LivaNova PLC Stock price

Equities

LIVN

GB00BYMT0J19

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
55.87 USD +2.72% Intraday chart for LivaNova PLC -1.34% +7.98%
Sales 2024 * 1.2B Sales 2025 * 1.26B Capitalization 3.01B
Net income 2024 * 63M Net income 2025 * 242M EV / Sales 2024 * 2.42 x
Net cash position 2024 * 102M Net cash position 2025 * 231M EV / Sales 2025 * 2.2 x
P/E ratio 2024 *
42.8 x
P/E ratio 2025 *
31 x
Employees 2,900
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.42%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.72%
1 week-1.34%
Current month+1.93%
1 month-0.05%
3 months+7.03%
6 months+5.06%
Current year+7.98%
More quotes
1 week
54.28
Extreme 54.28
56.56
1 month
49.70
Extreme 49.695
57.18
Current year
47.79
Extreme 47.79
57.80
1 year
41.87
Extreme 41.87
59.86
3 years
40.26
Extreme 40.26
93.89
5 years
33.40
Extreme 33.4
98.97
10 years
33.40
Extreme 33.4
131.54
More quotes
Managers TitleAgeSince
Chairman 72 18-06-11
Director of Finance/CFO 54 16-12-31
Chief Tech/Sci/R&D Officer - 18-01-07
Members of the board TitleAgeSince
Director/Board Member 63 20-12-02
Director/Board Member 64 22-06-12
Chairman 72 18-06-11
More insiders
Date Price Change Volume
24-03-27 55.87 +2.72% 416,464
24-03-26 54.39 -0.06% 811,121
24-03-25 54.42 -2.79% 394,030
24-03-22 55.98 -0.53% 519,752
24-03-21 56.28 -0.62% 1,435,391

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
LivaNova PLC is a global medical device company. The Company designs, develops, manufactures, and sells products and therapies to provide improvements for both the head and heart. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the development, production and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannulae and other related accessories. The Neuromodulation segment is engaged in the design, development, and marketing of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the LivaNova Vagus Nerve Stimulation Therapy (VNS Therapy) System, is an implantable device for the treatment of DRE and DTD. The ACS segment is engaged in the development, production, and sale of temporary life support products.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
55.87 USD
Average target price
66.5 USD
Spread / Average Target
+19.03%
Consensus
  1. Stock
  2. Equities
  3. Stock LivaNova PLC - Nasdaq